Carnosic Acid Encapsulated in Albumin Nanoparticles Induces Apoptosis in Breast and Colorectal Cancer Cells.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
25 Jun 2022
Historique:
received: 07 05 2022
revised: 16 06 2022
accepted: 17 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Carnosic acid (CA) is a natural phenolic compound with several biomedical actions. This work was performed to study the use of CA-loaded polymeric nanoparticles to improve the antitumor activity of breast cancer cells (MCF-7) and colon cancer cells (Caco-2). CA was encapsulated in bovine serum albumin (BSA), chitosan (CH), and cellulose (CL) nanoparticles. The CA-loaded BSA nanoparticles (CA-BSA-NPs) revealed the most promising formula as it showed good loading capacity and the best release rate profile as the drug reached 80% after 10 h. The physicochemical characterization of the CA-BSA-NPs and empty carrier (BSA-NPs) was performed by the particle size distribution analysis, transmission electron microscopy (TEM), and zeta potential. The antitumor activity of the CA-BSA-NPs was evaluated by measuring cell viability, apoptosis rate, and gene expression of GCLC, COX-2, and BCL-2 in MCF-7 and Caco-2. The cytotoxicity assay (MTT) showed elevated antitumor activity of CA-BSA-NPs against MCF-7 and Caco-2 compared to free CA and BSA-NPs. Moreover, apoptosis test data showed an arrest of the Caco-2 cells at G

Identifiants

pubmed: 35807348
pii: molecules27134102
doi: 10.3390/molecules27134102
pmc: PMC9268188
pii:
doi:

Substances chimiques

Abietanes 0
Drug Carriers 0
Proto-Oncogene Proteins c-bcl-2 0
Serum Albumin, Bovine 27432CM55Q
Cyclooxygenase 2 EC 1.14.99.1
salvin LI791SXT24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Nanomedicine. 2019 Aug 29;14:6971-6988
pubmed: 31507319
Polymers (Basel). 2021 Sep 29;13(19):
pubmed: 34641156
Front Oncol. 2020 Sep 09;10:577280
pubmed: 33014883
Pharm Res. 2004 Apr;21(4):671-4
pubmed: 15139524
Nutrients. 2020 Jun 10;12(6):
pubmed: 32532056
Int J Mol Sci. 2014 Jul 17;15(7):12698-713
pubmed: 25036034
Front Pharmacol. 2018 Sep 07;9:976
pubmed: 30245627
Mol Carcinog. 2016 Jun;55(6):1096-110
pubmed: 26152521
Curr Drug Metab. 2012 Jan;13(1):120-8
pubmed: 21892919
Evid Based Complement Alternat Med. 2019 Nov 16;2019:7623830
pubmed: 31827560
Amino Acids. 2020 Apr;52(4):555-566
pubmed: 32170467
Biology (Basel). 2021 Dec 06;10(12):
pubmed: 34943193
Chem Biol Interact. 2017 Nov 1;277:91-100
pubmed: 28918123
J Pharm Sci. 2011 Aug;100(8):3139-3145
pubmed: 21360710
Phytochemistry. 2015 Jul;115:9-19
pubmed: 25639596
J Drug Target. 2013 Jan;21(1):44-53
pubmed: 23020597
Front Bioeng Biotechnol. 2020 Jan 31;7:489
pubmed: 32083068
Metallomics. 2021 Jul 2;13(7):
pubmed: 34114030
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
Int J Pharm. 2021 Sep 25;607:121034
pubmed: 34425193
Front Pharmacol. 2021 Oct 11;12:661217
pubmed: 34721007
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Pharm Sci. 2021 Sep;110(9):3298-3305
pubmed: 34097977
Jpn J Clin Oncol. 2018 Apr 01;48(4):303-307
pubmed: 29474642
Cancer Treat Res Commun. 2022 Jan 7;30:100509
pubmed: 35026535
Cell Death Differ. 2018 Jan;25(1):65-80
pubmed: 29149100
Cells. 2021 Oct 27;10(11):
pubmed: 34831124
Int J Nanomedicine. 2016 Mar 07;11:929-40
pubmed: 27022260
J Cancer. 2019 Jun 2;10(15):3333-3343
pubmed: 31293636
3 Biotech. 2020 Sep;10(9):407
pubmed: 32904337
Cancer Treat Res Commun. 2021;27:100308
pubmed: 33465562
Front Nutr. 2021 Dec 01;8:783831
pubmed: 34926557
Sci Rep. 2020 Mar 27;10(1):5569
pubmed: 32221371
Oncotarget. 2017 Mar 2;8(12):20309-20327
pubmed: 28411284
Pharmaceutics. 2020 Dec 06;12(12):
pubmed: 33291312
Foods. 2021 Dec 28;11(1):
pubmed: 35010191
PLoS One. 2015 Mar 19;10(3):e0118870
pubmed: 25789740
Molecules. 2021 Dec 14;26(24):
pubmed: 34946671
Dose Response. 2020 Jul 10;18(3):1559325820936161
pubmed: 32699536
Int J Nanomedicine. 2020 Oct 14;15:7937-7949
pubmed: 33116510

Auteurs

Katren F Khella (KF)

Department of Pharmaceutical Biotechnology, College of Biotechnology, Misr University of Science and Technology, Giza 3236101, Egypt.

Ahmed I Abd El Maksoud (AI)

Department of Pharmaceutical Biotechnology, College of Biotechnology, Misr University of Science and Technology, Giza 3236101, Egypt.
Department of Industrial Biotechnology, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City 32897, Egypt.

Amr Hassan (A)

Department of Bioinformatics, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City 32897, Egypt.

Shaimaa E Abdel-Ghany (SE)

Department of Environmental Biotechnology, College of Biotechnology, Misr University of Science and Technology, Giza 3236101, Egypt.

Rafaat M Elsanhoty (RM)

Department of Industrial Biotechnology, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City 32897, Egypt.

Mohammed Abdullah Aladhadh (MA)

Department of Food Science and Human Nutrition, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah 51452, Saudi Arabia.

Mohamed A Abdel-Hakeem (MA)

Department of Pharmaceutical Biotechnology, College of Biotechnology, Misr University of Science and Technology, Giza 3236101, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH